Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report sent to investors on Thursday morning. The brokerage issued a hold rating on the stock.

Tonix Pharmaceuticals Trading Down 11.1 %

Shares of TNXP opened at $0.26 on Thursday. Tonix Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $12.48. The firm has a market capitalization of $47.84 million, a P/E ratio of 0.00 and a beta of 2.02. The firm has a 50-day moving average price of $0.25 and a 200 day moving average price of $0.33. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Sell-side analysts forecast that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.